177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy

[1]  Xiaoyuan Chen,et al.  First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  K. Rahbar,et al.  Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  R. Baum,et al.  Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies , 2018, The Journal of Nuclear Medicine.

[4]  M. Javadi,et al.  Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms , 2018, The Journal of Nuclear Medicine.

[5]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? , 2018, The Journal of Nuclear Medicine.

[6]  R. Schibli,et al.  Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. , 2018, Molecular pharmaceutics.

[7]  James M. Kelly,et al.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  K. Rahbar,et al.  18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  G. Kristiansen,et al.  Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role , 2018, The Journal of urology.

[10]  U. Haberkorn,et al.  Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers , 2017, The Journal of Nuclear Medicine.

[11]  K. Rahbar,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[12]  J. Czernin,et al.  Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[13]  C. Anderson,et al.  177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice , 2017, Theranostics.

[14]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[15]  M. Pomper,et al.  A PSMA-targeted theranostic agent for photodynamic therapy. , 2017, Journal of photochemistry and photobiology. B, Biology.

[16]  M. Brechbiel,et al.  (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy , 2016, The Journal of Nuclear Medicine.

[17]  R. Mease,et al.  Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. , 2016, Bioconjugate chemistry.

[18]  U. Haberkorn,et al.  New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy , 2016, Clinical Cancer Research.

[19]  Steve Y. Cho,et al.  Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[20]  U. Haberkorn,et al.  68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  M. Pomper,et al.  Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen , 2015, The Journal of Nuclear Medicine.

[22]  Michael Lassmann,et al.  68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.

[23]  M. Pomper,et al.  Prostate-specific membrane antigen as a target for cancer imaging and therapy. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[24]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[25]  M. Brechbiel,et al.  Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates , 2015, The Journal of Nuclear Medicine.

[26]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  M. Pomper,et al.  64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer , 2014, Journal of medicinal chemistry.

[28]  M. Pomper,et al.  Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). , 2013, Journal of medicinal chemistry.

[29]  Shankar Vallabhajosula,et al.  Prostate-specific membrane antigen-based imaging. , 2013, Urologic oncology.

[30]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[31]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[32]  J. Ward,et al.  Pathobiology of Aging Mice and GEM , 2012, Veterinary pathology.

[33]  M. Pomper,et al.  Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. , 2011, Angewandte Chemie.

[34]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[35]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[36]  Ming Zhou,et al.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. , 2006, Urology.

[37]  J. Neale,et al.  NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR , 2004, Journal of neurochemistry.

[38]  George Sgouros,et al.  MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  L. Serfilippi,et al.  Serum clinical chemistry and hematology reference values in outbred stocks of albino mice from three commonly used vendors and two inbred strains of albino mice. , 2003, Contemporary topics in laboratory animal science.

[40]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[42]  Kratochwil Clemens,et al.  Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Dosimetry estimate and empirical dose finding , 2017 .

[43]  C. Brayton.  Spontaneous Diseases in Commonly Used Mouse Strains , 2007 .

[44]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.